Aurisco Pharmaceutical Co Ltd
Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of pharmaceutical intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provid… Read more
Aurisco Pharmaceutical Co Ltd (605116) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.47 Billion CNY
Based on the latest financial reports, Aurisco Pharmaceutical Co Ltd (605116) has total liabilities worth CN¥1.47 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aurisco Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Aurisco Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aurisco Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Aurisco Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liuzhou Chemical Industry Co Ltd
SHG:600423
|
China | CN¥59.12 Million |
|
Jiangsu WELLE Environmental Co Ltd
SHE:300190
|
China | CN¥4.41 Billion |
|
K-Bro Linen Inc.
TO:KBL
|
Canada | CA$440.76 Million |
|
Volex plc
PINK:VLXGF
|
USA | $553.10 Million |
|
Flytech Technology Co Ltd
TW:6206
|
Taiwan | NT$983.84 Million |
|
Shenzhen Sosen Electronics Co.Ltd.
SHE:301002
|
China | CN¥662.61 Million |
|
Propel Funeral Partners Limited
PINK:PFPLF
|
USA | $300.05 Million |
|
Regal Partners Ltd
AU:RPL
|
Australia | AU$164.10 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Aurisco Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aurisco Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aurisco Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total liabilities of Aurisco Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.55 Billion | +154.67% |
| 2023-12-31 | CN¥607.03 Million | +74.09% |
| 2022-12-31 | CN¥348.68 Million | +63.37% |
| 2021-12-31 | CN¥213.44 Million | +44.23% |
| 2020-12-31 | CN¥147.98 Million | +20.34% |
| 2019-12-31 | CN¥122.96 Million | -7.65% |
| 2018-12-31 | CN¥133.16 Million | +0.54% |
| 2017-12-31 | CN¥132.44 Million | -31.03% |
| 2016-12-31 | CN¥192.01 Million | -- |